Incriminating paperwork revealed in Purdue’s OxyContin case
Emails, slide decks, and other documents will be released as part of the Purdue Pharma litigation.
According to documents released by a congressional committee, members of Purdue’s Sackler family used OxyContin sales to “meet financial goals and pressure company executives to increase their opioid market share by targeting high volume prescribers aim and take higher doses ”. Internal emails, presentations and financial charts posted also note how members of the Sackler family “treated one of their opioids as a cash cow” and withdrew around $ 10 billion from Purdue since 2008.
The document’s disclosure follows an agreement to plead guilty to three crimes in a $ 8.3 billion settlement that also resolves civil claims. As part of the deal, Purdue admitted to misleading the Drug Enforcement Administration (DEA) about a program to monitor doctor diversion, falsify information to increase manufacturing rates and violate kickback laws. The federal prosecutor’s office confirmed that the criminal investigation has not yet been concluded.
“The documents we are releasing today show that members of the Sackler family – and especially Dr. Richard Sackler – who ruthlessly urged Purdue executives to flood the market with OxyContin to maximize their personal wealth, even after the company reached an agreement with the DOJ in 2007 for misleading marketing, “said Carolyn Maloney (DN.Y .), Chair of the House Committee on Oversight and Reform, in a statement with committee member Mark DeSaulnier (D-CA.).
“We are disappointed that the DOJ has missed yet another opportunity to hold members of the Sackler family fully accountable for their role in starting the devastating opioid epidemic,” they wrote, noting that members of the Sackler family disregard themselves agreed to pay $ 225 million in damages to resolve civil liability, but that amount is only 2% of the family’s estimated net worth of $ 13 billion. “
In one such email, which Mortimer Sackler wrote to Purdue’s board of directors in October 2013, said, “The organization appears to have just given up completely and is resigned to reducing sales of all of our products, which is bad for our business and our pipeline is very bad (and I would) again question the value of investing so heavily in an R&D pipeline whose future is very questionable given the dramatic changes in the market. “
In June 2011 Richard Sackler reviewed a report on salespeople and wrote, “It is suggested above that we do not call potential prescribers. How can our managers have allowed this? “In August 2013, he arranged a meeting between Purdue board members and McKinsey consultants to” discuss a McKinsey plan to “turbo-charge the distributor” for OxyContin “.
Daniel Connolly, an attorney for Raymond Sackler, responded, “The publication of Purdue documents will definitely show that Sackler family members who served on Purdue’s board of directors have received repeated assurances that all sales and marketing activities are in accordance with legal and regulatory requirements and that this program was consistent with industry best practices. We will continue to work constructively on a final resolution of the legal cases – if Purdue’s documents are quickly available for public scrutiny and correct the inaccurate impressions created by this type of selective publication of cherry-picked documents. “
Purdue will be converted into a nonprofit operated on behalf of the U.S. communities that is litigating Purdue over the opioid epidemic and members of the Sackler family would give up control.
Legislature publishes a plethora of Purdue documents listing the Sackler family’s involvement in opioid sales